Moderna-Merck personalised melanoma vaccine extends relapse-free survival in first late-stage trial

A personalised cancer vaccine developed by Moderna and Merck has shown promising results in the first late-stage clinical trial for melanoma. The combination regimen significantly extended the time patients lived without their cancer returning, compared with Keytruda alone. The findings mark a major step forward for individualised cancer treatment.